Synfini Inc. and O2nix Bio Announce Strategic Collaboration to Develop Novel Cancer Therapeutics Targeting FTSJ1
Combination of World Leading Epitranscriptomics and AI-Driven Automation Aims to Accelerate Development of Cancer Therapies That Halt Metastasis
Excerpt from the Press Release:
MENLO PARK, Calif. and CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) — Synfini Inc., a leader in AI-driven drug discovery, and O2nix Bio, a pioneering biotech company advancing prooxidant therapies, today announced a strategic collaboration to co-discover and develop novel drug candidates targeting FTSJ1, a tRNA-modifying enzyme implicated in metastatic cancer cell survival. This is O2nix Bio’s first collaboration as an independent, privately funded commercial entity, building on its extensive research into biochemical mechanisms that regulate metastasis.
The collaboration will combine O2nix Bio’s proprietary biology platform and scientific leadership in tRNA methylation with Synfini’s AI Cloud Foundry, an end-to-end automated system that accelerates the design-make-test-analyze (DMTA) drug discovery cycle.
“We are thrilled to collaborate with the Synfini team,” said Elena Piskounova, Ph.D., founder and CEO of O2nix Bio. “Their chemistry automation platform, paired with our mechanistic insights into RNA modifications, will allow us to advance first-in-class therapies targeting cancer metastasis—which is responsible for over 90% of cancer-related deaths and still largely untreatable by current therapies.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?